MAP2K7 and cancer: Our finding provides a probable explanation for the response heterogeneity of MEK inhibition in cancer treatment [3] because the regulatory effect of MEK inhibition on PDE4D activity largely depends on the cell-type/environment [8, 39] and finally leads to the different change of cAMP level.